Cargando…

New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Sevelamer hydrochloride is used widely, but its impact upon cardiovascular calcification, cardiovascular mortality, all-cause mortality and hospitalization is not known. OUTCOMES: Primary outcome was cardiovascular calcification (coronary artery calcification scores (CACS) and aortic cal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Caixia, Liu, Xun, Zhou, Yongming, Li, Shaomin, Chen, Yanbing, Wang, Yanni, Lou, Tanqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521824/ https://www.ncbi.nlm.nih.gov/pubmed/26230677 http://dx.doi.org/10.1371/journal.pone.0133938

Ejemplares similares

Long-Term Effects of Sevelamer on Vascular Calcification, Arterial Stiffness, and Calcification Propensity in Patients Receiving Peritoneal Dialysis: The Randomized Pilot SERENE (Sevelamer on Vascular Calcification, Arterial Stiffness) Trial
por: Wang, Angela Yee-Moon, et al.
Publicado: (2021)

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
por: Nadin, Carole
Publicado: (2005)

Sevelamer Attenuates Bioprosthetic Heart Valve Calcification
por: Meng, Zhen, et al.
Publicado: (2021)

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
por: Nain, Parminder, et al.
Publicado: (2023)

Correlation between Serum Lipid Levels and Measured Glomerular Filtration Rate in Chinese Patients with Chronic Kidney Disease
por: Wang, Yanni, et al.
Publicado: (2016)

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial
por: Smith, Edward R., et al.
Publicado: (2020)

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability
por: de Francisco, Angel L.M., et al.
Publicado: (2010)

A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis
por: Zhou, Tianbiao, et al.
Publicado: (2018)

Do we need new phosphate binders in dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2020)

Phosphate binders in dialysis: better satisfied than sorry
por: Cozzolino, Mario, et al.
Publicado: (2021)

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients
por: Gonzalez, Elsa, et al.
Publicado: (2010)

Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease
por: Mason, Darius L., et al.
Publicado: (2021)

Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2023)

The demise of calcium-based phosphate binders—is this appropriate for children?
por: Rees, Lesley, et al.
Publicado: (2014)

Comparison of Sevelamer and Calcium Carbonate in Prevention of Hypomagnesemia in Hemodialysis Patients
por: Jandaghi, Elahe, et al.
Publicado: (2021)

Interventional study to improve adherence to phosphate binder treatment in dialysis patients
por: Hjemås, Bodil Jahren, et al.
Publicado: (2019)

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
por: Phan, Olivier, et al.
Publicado: (2015)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Effects of the Use of Non-Calcium Phosphate Binders in the Control and Outcome of Vascular Calcifications: A Review of Clinical Trials on CKD Patients
por: Bolasco, Piergiorgio
Publicado: (2011)

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China
por: Meng, Lin, et al.
Publicado: (2015)

Serum irisin levels correlated to peritoneal dialysis adequacy in nondiabetic peritoneal dialysis patients
por: Tan, Zhijun, et al.
Publicado: (2017)

Improving precision of glomerular filtration rate estimating model by ensemble learning
por: Liu, Xun, et al.
Publicado: (2017)

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis
por: Tanaka, Akihito, et al.
Publicado: (2023)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia
por: De Schutter, Tineke M, et al.
Publicado: (2013)

Conclusions in Regard to Gastrotomy
Publicado: (1878)

Molecular Modeling Studies of the Binding Characteristics of Phosphates to Sevelamer Hydrochloride – Assessing a Novel Technique to Reduce Phosphates Contamination
por: Parker, R., et al.
Publicado: (2006)

Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer
por: Ghorbanihaghjo, Amir, et al.
Publicado: (2018)

Ischemic Colitis in Association with Sevelamer Crystals
por: Keri, K. C., et al.
Publicado: (2019)

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Sevelamer Carbonate Crystal-Induced Colitis
por: Lai, T., et al.
Publicado: (2020)

Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency
por: Jokihaara, Jarkko, et al.
Publicado: (2016)

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature
por: Cataldo, Emanuela, et al.
Publicado: (2018)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
por: Hashimoto, Hiroko, et al.
Publicado: (2021)

Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients
por: Mahdavi, Sara, et al.
Publicado: (2019)

Sevelamer-Induced Gastrointestinal Injury Presenting as Gastroenteritis
por: Magee, Jared, et al.
Publicado: (2018)

Binding interactions with sevelamer and polystyrene sulfonate in vitro
por: van Berlo‐van de Laar, Inge R.F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ak4kbej4ed56ddq3n9nutk78kt